Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 7, 2026, 10:36 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–13 of 13 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Ustekinumab (6 mg/kg) Clear all

Conditions: Lupus Erythematosus, Systemic
Interventions: Ustekinumab IV, Placebo Infusion, Placebo SC, Ustekinumab SC, Concomitant Medication; Drug · Other
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 102 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 12
States / cities: Huntsville, Alabama • Beverly Hills, California • Tampa, Florida + 9 more

Conditions: Colitis, Ulcerative, Inflammatory Bowel Diseases
Interventions: Placebo IV, Placebo SC, Ustekinumab IV, Ustekinumab SC; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 961 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2021
U.S. locations: 68
States / cities: Birmingham, Alabama • La Mirada, California • Los Angeles, California + 65 more

Conditions: Crohn Disease
Interventions: Placebo for Ustekinumab, Placebo for Adalimumab, Ustekinumab (6 mg/kg), Ustekinumab (90 mg), Adalimumab (40 mg); Biological
Lead sponsor: Janssen Scientific Affairs, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 386 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 67
States / cities: Mobile, Alabama • San Diego, California • Colorado Springs, Colorado + 60 more

Conditions: Crohn's Disease, Inflammatory Bowel Disease, IBD, Colitis
Interventions: Group 1: Placebo, Group 2 ustekinumab 130 mg, Group 3: ustekinumab approximately 6 mg/kg; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 640 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 84
States / cities: Tucson, Arizona • Little Rock, Arkansas • La Jolla, California + 81 more

Conditions: Crohn's Disease
Interventions: Placebo (IP), Ustekinumab 1mg/kg (IP), Ustekinumab 3 mg/kg (IP), Ustekinumab 6 mg/kg (IP), Placebo IV - Responder - Placebo SC (MP), Placebo IV - Nonresponder - Ustekinumab 270/90 mg SC (MP), Ustekinumab IV - Responder - Placebo SC (MP), Ustekinumab IV - Responder - Ustekinumab 90mg SC (MP), Ustekinumab IV - Nonresponder - Placebo SC (MP), Ustekinumab IV - Nonresponder - Ustekinumab 90mg SC (MP); Drug
Lead sponsor: Centocor, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 526 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 88
States / cities: Mobile, Alabama • Scottsdale, Arizona • La Jolla, California + 85 more

Conditions: Psoriasis
Interventions: Ustekinumab 0.75 mg/kg, Ustekinumab 45 mg, Ustekinumab 90 mg; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 6 Years to 11 Years
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 7
States / cities: San Diego, California • Chicago, Illinois • Indianapolis, Indiana + 4 more

Conditions: Healthy
Interventions: Ustekinumab; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 140 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014
U.S. locations: 3
States / cities: Tempe, Arizona • Lincoln, Nebraska • Neptune City, New Jersey

Conditions: Lupus Erythematosus, Systemic
Interventions: Placebo, Ustekinumab (approximately 6 mg/kg), Ustekinumab 90 mg; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 16 Years to 75 Years
Enrollment: 516 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 69
States / cities: Anniston, Alabama • Birmingham, Alabama • Vestavia Hills, Alabama + 56 more

Conditions: Crohn's Disease
Interventions: Mirikizumab, Ustekinumab, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 15 Years to 80 Years
Enrollment: 1,158 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 140
States / cities: Birmingham, Alabama • Dothan, Alabama • Guntersville, Alabama + 113 more

Conditions: Crohn Disease
Interventions: Ustekinumab approximately 6 mg/kg (IV), Placebo (SC), Placebo (IV), Ustekinumab 90 mg (SC) Group 1, Ustekinumab 90 mg (SC) Group 2; Drug
Lead sponsor: Janssen-Cilag Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 215 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 28
States / cities: La Jolla, California • Colorado Springs, Colorado • Gainesville, Florida + 22 more

Conditions: Crohn's Disease, IBD, Colitis, Inflammatory Bowel Disease
Interventions: Group 2 ustekinumab 130 mg, Group 3: ustekinumab approximately 6 mg/kg, Group 1: Placebo; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 769 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 67
States / cities: Tucson, Arizona • Little Rock, Arkansas • La Jolla, California + 64 more

Conditions: Primary Sjögren Syndrome
Interventions: Ustekinumab; Drug
Lead sponsor: University of Rochester; Other
Eligibility: 18 Years to 75 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Crohn Disease
Interventions: JNJ-64304500, Placebo, Ustekinumab; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 388 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2022
U.S. locations: 37
States / cities: Lone Tree, Colorado • Coral Gables, Florida • Kissimmee, Florida + 34 more

Search by objective public record fields.

A Phase 2a, Efficacy and Safety Study of Ustekinumab in Systemic Lupus Erythematosus

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction and Maintenance Therapy in Participants With Moderately to Severely Active Ulcerative Colitis

Safety and Efficacy of Adalimumab Versus Ustekinumab for One Year

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

A Study of Safety and Effectiveness of Ustekinumab in Patients With Moderate to Severe Active Crohn's Disease Who Have Been Previously Treated With Anti-TNF Therapy

An Efficacy, Safety, and Pharmacokinetics Study of Subcutaneously Administered Ustekinumab in the Treatment of Moderate to Severe Chronic Plaque Psoriasis in Pediatric Participants Greater Than or Equal to 6 to Less Than 12 Years of Age

A Pharmacokinetic Study of Single-Dose Intravenous Ustekinumab Delivered in 2 Different Liquid in Vial Formulations

A Study of Ustekinumab in Participants With Active Systemic Lupus Erythematosus

A Study of Mirikizumab (LY3074828) in Participants With Crohn's Disease

A Study to Evaluate Efficacy and Safety of Ustekinumab Re-induction Therapy in Participants With Moderately to Severely Active Crohn's Disease

A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)

Pilot Trial of Ustekinumab for Primary Sjögren's Syndrome

Safety and Efficacy Study of JNJ-64304500 in Participants With Moderately to Severely Active Crohn's Disease